Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer
Leukemia Centralized Reference Laboratories and Tissue Repositories - Ancillary
Status: Archived
Welch Cancer Center
mi
from
Sheridan, WY
Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer
Leukemia Centralized Reference Laboratories and Tissue Repositories - Ancillary
Status: Archived
Updated: 1/1/1970
Welch Cancer Center
mi
from
Sheridan, WY
A Pharmacokinetic Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
A Phase IIA Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Status: Archived
University of Kansas Medical Center
mi
from
Kansas City, KA
A Pharmacokinetic Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
A Phase IIA Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Status: Archived
Updated: 1/1/1970
University of Kansas Medical Center
mi
from
Kansas City, KA
A Pharmacokinetic Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
A Phase IIA Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Status: Archived
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Pharmacokinetic Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
A Phase IIA Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCL for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Status: Archived
Updated: 1/1/1970
Medical College of Wisconsin
mi
from
Milwaukee, WI
Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal GVHD
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal GVHD
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal GVHD
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal GVHD
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal GVHD
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal GVHD
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
VA Medical Center, Loma Linda
mi
from
Loma Linda, CA
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Updated: 1/1/1970
VA Medical Center, Loma Linda
mi
from
Loma Linda, CA
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
University of Colorado, Boulder
mi
from
Boulder, CO
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
mi
from
Boulder, CO
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Henry Ford Hospital
mi
from
Detroit, MI
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Updated: 1/1/1970
Henry Ford Hospital
mi
from
Detroit, MI
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Emergency Medicine Research Group
mi
from
Lansing, MI
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Updated: 1/1/1970
Emergency Medicine Research Group
mi
from
Lansing, MI
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Cardiac and Vascular Research Center of Northern Michigan
mi
from
Petoskey, MI
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Updated: 1/1/1970
Cardiac and Vascular Research Center of Northern Michigan
mi
from
Petoskey, MI
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
The International Heart Institute of Montana
mi
from
Missoula, MT
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Updated: 1/1/1970
The International Heart Institute of Montana
mi
from
Missoula, MT
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
University of New Mexico
mi
from
Albuquerque, NM
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Updated: 1/1/1970
University of New Mexico
mi
from
Albuquerque, NM
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
New York Methodist Hospital
mi
from
Brooklyn, NY
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Updated: 1/1/1970
New York Methodist Hospital
mi
from
Brooklyn, NY
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
John T Mather Memorial Hospital
mi
from
Port Jefferson, NY
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Updated: 1/1/1970
John T Mather Memorial Hospital
mi
from
Port Jefferson, NY
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Northwest Heart Center
mi
from
Tomball, TX
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Updated: 1/1/1970
Northwest Heart Center
mi
from
Tomball, TX
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Swedish Medical Center
mi
from
Seattle, WA
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Updated: 1/1/1970
Swedish Medical Center
mi
from
Seattle, WA
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Status: Archived
Updated: 1/1/1970
Wenatchee Valley Medical Center
mi
from
Wenatchee, WA
Busulfan in Multiple Myeloma
A Phase I/II Open Label Study of IV Busulfan (Busulfex®) in Multiple Myeloma Patients 65 Years of Age or Older, or With Renal Insufficiency Undergoing Autologous Transplantation
Status: Archived
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Busulfan in Multiple Myeloma
A Phase I/II Open Label Study of IV Busulfan (Busulfex®) in Multiple Myeloma Patients 65 Years of Age or Older, or With Renal Insufficiency Undergoing Autologous Transplantation
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
Induction of Anti-Myeloma Stem Cell Immunity With Infusions of Autologous Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) (Phase I).
Status: Archived
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
Induction of Anti-Myeloma Stem Cell Immunity With Infusions of Autologous Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) (Phase I).
Status: Archived
Updated: 1/1/1970
Wayne State University/Detroit Medical Center
mi
from
Detroit, MI
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
Induction of Anti-Myeloma Stem Cell Immunity With Infusions of Autologous Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) (Phase I).
Status: Archived
Sinai-Grace Hospital
mi
from
Detroit, MI
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
Induction of Anti-Myeloma Stem Cell Immunity With Infusions of Autologous Activated T Cells Armed With OKT3 x Rituxan (Anti-CD3 x Anti-CD20) Bispecific Antibody (CD20Bi) (Phase I).
Status: Archived
Updated: 1/1/1970
Sinai-Grace Hospital
mi
from
Detroit, MI
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Status: Archived
University of Illinois College of Medicine
mi
from
Chicago, IL
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Status: Archived
Updated: 1/1/1970
University of Illinois College of Medicine
mi
from
Chicago, IL
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Status: Archived
University of Utah
mi
from
Salt Lake City, UT
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Status: Archived
Updated: 1/1/1970
University of Utah
mi
from
Salt Lake City, UT
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
A Phase I/II Study of Vaccination Against Minor Histocompatibility Antigens HA1 or HA2 After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
Status: Archived
University of Chicago
mi
from
Chicago, IL
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
A Phase I/II Study of Vaccination Against Minor Histocompatibility Antigens HA1 or HA2 After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Clofarabine-melphalan-alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Status: Archived
University of Chicago
mi
from
Chicago, IL
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Clofarabine-melphalan-alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
Controlling Blood Sugar Levels in Preventing Infection in Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Effects of Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Controlling Blood Sugar Levels in Preventing Infection in Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Effects of Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Darien Pediatric Associates
mi
from
Darien, CT
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
mi
from
Darien, CT
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Clinical Research Facility
mi
from
Orlando, FL
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Orlando, FL
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Clinical Research Facility
mi
from
New Orleans, LA
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
New Orleans, LA
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Clinical Research Facility
mi
from
Ann Arbor, MI
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Ann Arbor, MI
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Clinical Research Facility
mi
from
Kansas City, MO
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Kansas City, MO
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Clinical Research Facility
mi
from
Lebanon, NH
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Lebanon, NH
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Clinical Research Facility
mi
from
Albany, NY
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Albany, NY
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Clinical Research Facility
mi
from
Columbus, OH
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Columbus, OH
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Clinical Research Facility
mi
from
Allentown, PA
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Allentown, PA
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Clinical Research Facility
mi
from
Sioux Falls, SD
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Sioux Falls, SD
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Clinical Research Facility
mi
from
Memphis, TN
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Memphis, TN
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Clinical Research Facility
mi
from
Austin, TX
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Austin, TX
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Clinical Research Facility
mi
from
Milwaukee, WI
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
A Prospective, Multicenter, Open Enrollment Study of Human Plasma Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Milwaukee, WI
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
The Bleeding and Clotting Disorders Institute
mi
from
Peoria, IL
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
The Bleeding and Clotting Disorders Institute
mi
from
Peoria, IL
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
St. Vincent Indianapolis Hospital
mi
from
Indianapolis, IN
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
St. Vincent Indianapolis Hospital
mi
from
Indianapolis, IN
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
New England Hemophilia Center
mi
from
Worcester, MA
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
New England Hemophilia Center
mi
from
Worcester, MA
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Vanderbilt Hemostatis and Thrombosis Clinic
mi
from
Nashville, TN
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
Vanderbilt Hemostatis and Thrombosis Clinic
mi
from
Nashville, TN
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Puget Sound Blood Center
mi
from
Seattle, WA
Study of Ataluren (PTC124®) in Hemophilia A and B
A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B
Status: Archived
Updated: 1/1/1970
Puget Sound Blood Center
mi
from
Seattle, WA
Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA